| Kelly Mahoney, PMHNP | |
|
33 Tower St, Somerville, MA 02143-1426 | |
| (617) 591-4500 | |
| Not Available |
| Full Name | Kelly Mahoney |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 33 Tower St, Somerville, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922580026 | NPI | - | NPPES |
| Entity Name | Caldwell Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477839108 PECOS PAC ID: 5395646970 Enrollment ID: O20040116000355 |
News Archive
Chemists at the University of Burgos (Spain) have manufactured a sheet that changes colour in the presence of water contaminated with mercury. The results can be seen with the naked eye but when photographing the membrane with a mobile phone the concentration of this extremely toxic metal can be quantified.
The Devex "Development Newswire" blog provides a comprehensive round-up of sessions, events, and reports from the third day (July 24) of the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., including a summary of a session that discussed how Brazil, South Africa, India, and China contribute to the global AIDS response.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
A new national survey reveals a vast gap between how Canadians living with depression view their condition, compared to how it is viewed in reality by the general population, possibly preventing them from seeking the best treatment and care. Most Canadians with depression feel their illness is not perceived by the public as a medical condition or a serious illness (81 per cent) when in fact less than five per cent of the general population actually has that view. In fact, the majority of Canadians (72 per cent) recognize depression as both serious and treatable.
› Verified 3 days ago
| Entity Name | Mindpath Care Centers North Carolina Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508803214 PECOS PAC ID: 4688655517 Enrollment ID: O20040526001582 |
News Archive
Chemists at the University of Burgos (Spain) have manufactured a sheet that changes colour in the presence of water contaminated with mercury. The results can be seen with the naked eye but when photographing the membrane with a mobile phone the concentration of this extremely toxic metal can be quantified.
The Devex "Development Newswire" blog provides a comprehensive round-up of sessions, events, and reports from the third day (July 24) of the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., including a summary of a session that discussed how Brazil, South Africa, India, and China contribute to the global AIDS response.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
A new national survey reveals a vast gap between how Canadians living with depression view their condition, compared to how it is viewed in reality by the general population, possibly preventing them from seeking the best treatment and care. Most Canadians with depression feel their illness is not perceived by the public as a medical condition or a serious illness (81 per cent) when in fact less than five per cent of the general population actually has that view. In fact, the majority of Canadians (72 per cent) recognize depression as both serious and treatable.
› Verified 3 days ago
| Entity Name | Wakemed Specialists Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588227839 PECOS PAC ID: 2466788377 Enrollment ID: O20190731000815 |
News Archive
Chemists at the University of Burgos (Spain) have manufactured a sheet that changes colour in the presence of water contaminated with mercury. The results can be seen with the naked eye but when photographing the membrane with a mobile phone the concentration of this extremely toxic metal can be quantified.
The Devex "Development Newswire" blog provides a comprehensive round-up of sessions, events, and reports from the third day (July 24) of the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., including a summary of a session that discussed how Brazil, South Africa, India, and China contribute to the global AIDS response.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
A new national survey reveals a vast gap between how Canadians living with depression view their condition, compared to how it is viewed in reality by the general population, possibly preventing them from seeking the best treatment and care. Most Canadians with depression feel their illness is not perceived by the public as a medical condition or a serious illness (81 per cent) when in fact less than five per cent of the general population actually has that view. In fact, the majority of Canadians (72 per cent) recognize depression as both serious and treatable.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Mahoney, PMHNP 400 W Hargett St Apt 406, Raleigh, NC 27603-4059 Ph: (910) 603-6162 | Kelly Mahoney, PMHNP 33 Tower St, Somerville, MA 02143-1426 Ph: (617) 591-4500 |
News Archive
Chemists at the University of Burgos (Spain) have manufactured a sheet that changes colour in the presence of water contaminated with mercury. The results can be seen with the naked eye but when photographing the membrane with a mobile phone the concentration of this extremely toxic metal can be quantified.
The Devex "Development Newswire" blog provides a comprehensive round-up of sessions, events, and reports from the third day (July 24) of the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., including a summary of a session that discussed how Brazil, South Africa, India, and China contribute to the global AIDS response.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
A new national survey reveals a vast gap between how Canadians living with depression view their condition, compared to how it is viewed in reality by the general population, possibly preventing them from seeking the best treatment and care. Most Canadians with depression feel their illness is not perceived by the public as a medical condition or a serious illness (81 per cent) when in fact less than five per cent of the general population actually has that view. In fact, the majority of Canadians (72 per cent) recognize depression as both serious and treatable.
› Verified 3 days ago